Does Perineural Dexamethasone Increase the Duration of an Ulnar Nerve Block When Controlling for Systemic Effects?
Study Details
Study Description
Brief Summary
Investigators will assess if perineural dexamethasone can increase the duration of an ulnar nerve block when controlling for systemic effects in healthy volunteers.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
Healthy volunteers will have bilateral ulnar nerve blocks performed with bupivacaine on two different days with a minimum of 14 days wash-out. On one day, the participants will also receive dexamethasone in one arm and placebo in the other. On the other day, the participants will also receive placebo in one arm and lidocaine in the other. By this using this design, the investigators will be able to assess if perineural dexamethasone can increase the duration of an ulnar nerve block when controlling for the systemic effects. Furthermore, to ensure blinding, the investigators have also incorporated the lidocaine group which also allows for the assessment of the effects of adding lidocaine to a peripheral nerve block with bupivacaine. The order of which the participant will receive dexamethasone and lidocaine will be random. It will also be random in which arm the participant receives dexamethasone and lidocaine.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Perineural dexamethasone Bilateral ulnar nerve blocks with bupivacaine. Dexamethasone will be added perineurally in this arm on the same day as the 'systemic dexamethasone' group. |
Drug: Perineural dexamethasone
Dexamethasone 4mg will be added perineurally to an ulnar nerve block with bupivacaine.
|
Active Comparator: Systemic dexamethasone Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as the 'perineural dexamethasone' group. Thereby, this ulnar nerve block will only be affected by the perineurally added dexamethasone that is absorbed and redistributed systemically. |
Drug: Systemic dexamethasone
Dexamethasone will be added perineurally to an ulnar nerve block with bupivacaine, some will be reabsorbed and distributed systemically. Thereby, the investigators control for the systemic effects of adding perineural dexamethasone to an ulnar nerve block.
|
Placebo Comparator: Placebo Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as lidocaine group. This will be the actual placebo group. |
Drug: Placebo
Saline will be added perineurally to an ulnar nerve block with bupivacaine.
Other Names:
|
Active Comparator: Perineural lidocaine Bilateral ulnar nerve blocks with bupivacaine. Lidocaine will be added perineurally in this arm on the same day as the actual placebo group. |
Drug: Lidocaine
Lidocaine 40 mg will be added perineurally to an ulnar nerve block with bupivacaine.
|
Outcome Measures
Primary Outcome Measures
- Duration of the sensory nerve block, assessed by temperature discrimination (cold swab) [24 hours]
The investigators will stimulate the skin with an alcohol swab and ask the participant if it is cold or warm. The duration of the sensory block will be defined as the time to the alcohol swab feels cold again. The investigators will assess temperature discrimination every 30 minutes.
Secondary Outcome Measures
- Duration of the sensory nerve block, assessed by mechanical discrimination (pinprick) [24 hours]
The investigators will stimulate the skin with a needle. The duration of the sensory block will be defined as the time to the needle feels sharp again. The investigators will assess mechanical discrimination every 30 minutes.
- Duration of analgesia, assessed by pain during tonic heat stimulation (heated thermode) [24 hours]
The investigators will stimulate the participants' skin for 30 seconds with a thermode heated to 45 degrees Celsius. The participants rate the pain elicited on the Visual Analogue Scale using a ruler indicating "no pain" at zero millimetre on one end and "worst perceivable pain" at 100 millimetres at the opposite end. The duration of the sensory block will be defined as the time to the tonic heat stimulation elicits a painful response of Visual Analogue Scale above '0'. The investigators will assess pain every 30 minutes.
- Duration of the motor block, assessed by fifth finger abduction [24 hours]
The hand is placed facing with the volar side upwards. The hand is constricted so that only the fifth finger can abduct. The motor block is assessed using a Modified Bromage Scale. The duration of motor block is the time from block performance until Bromage grade '4' is reached or the participant indicates a feeling of normal strength in the finger.
- Onset of the sensory nerve block, assessed by temperature discrimination (cold swab) [24 hours]
The investigators will stimulate the skin with an alcohol swab and ask the participant if it is cold or warm. The onset of the sensory block will be defined as the time to the alcohol swab no longer feels cold. The investigators will assess the onset by temperature discrimination every 5 minutes.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age of 18 years or above
-
Must fully understand the protocol and sign written informed consent
-
American Society of Anaesthesiologists Physical Status Classification System of 1 or 2
-
Body Mass Index above 18 kg/m^2
-
For fertile women, safe contraceptives for the last month and negative urine human chorionic gonadotropin is required
Exclusion Criteria:
-
Participants unable to cooperate
-
Participants unable to speak or read Danish
-
Age above 65 years
-
Cardiovascular disease
-
Allergy to study medication
-
History of alcohol or substance abuse
-
Intake of corticosteroids within the last 14 days
-
Daily intake of prescription analgesia within the last four weeks
-
Intake of over-the-counter analgesia within the last 48 hours
-
Neuromuscular diseases or wounds on the arms or hands preventing adequate test or block performance.
-
Diabetes mellitus
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Zealand University Hospital | Køge | Zealand Region Of Denmark | Denmark | 4600 |
Sponsors and Collaborators
- Zealand University Hospital
Investigators
- Principal Investigator: Mathias Maagaard, MD, Zealand University Hospital, Køge
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- REG-138-2020